Neonatal abstinence syndrome: Treatment and pediatric outcomes

Clinical Obstetrics and Gynecology

Volumn 56, Issue 1, 2013, Pages 186-192

  Logan, Beth A ^a   Brown, Mark S ^b   Hayes, Marie J ^a,c  

^a University of Maine   (United States)

^b EASTERN MAINE MEDICAL CENTER   (United States)

^c Eastern Maine Healthcare Systems   (United States)

Author keywords

maternal opiate dependence; neonatal abstinence syndrome; neonatal and long term developmental outcomes; pharmacological treatment for opiate addiction

Indexed keywords

CANNABIS; CATECHOL METHYLTRANSFERASE; COCAINE; METHADONE; MU OPIATE RECEPTOR; OPIATE; OXYCODONE;

BIRTH WEIGHT; BLOOD PLACENTA BARRIER; BODY HEIGHT; BREAST FEEDING; CHILD DEVELOPMENT; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MISUSE; FETUS DEATH; FETUS OUTCOME; GENETIC RISK; HEAD CIRCUMFERENCE; HUMAN; LONG TERM EXPOSURE; MATERNAL PLASMA; METHADONE TREATMENT; MULTIPLE DRUG ABUSE; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRENATAL DRUG EXPOSURE; PRENATAL EXPOSURE; PRESCRIPTION; PSYCHOEDUCATION; SMOKING; SOCIAL STATUS; SYMPTOM ASSESSMENT; WITHDRAWAL SYNDROME; WORKING MEMORY;

DEVELOPMENTAL DISABILITIES; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; PRENATAL EXPOSURE DELAYED EFFECTS; SEVERITY OF ILLNESS INDEX;

EID: 84873405416     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31827feea4     Document Type: Conference Paper

References (37)

1. Paulozzi LJ, Xi Y. Recent changes in drug poison-ing mortality in the United States by urban-rural status and be drug type. Pharmacoepidemiology andDrug Safety. 2008;17:997-1005.
2. US Deptartment of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. NATIONAL SURVEY ON DRUG USE AND HEALTH, 2008 [Computer file]. ICPSR26701-v2. Research Triangle Park, NC: Research Triangle Institute [producer], 2012. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor]. 2012.
3. Finnegan LP, Hagan T, Kaltenbach KA. Scien-tific foundation ofclinical practice: opiate use in pregnant women. Bull N Y Acad Med. 1991;67: 223-239.
4. Oei J, Lui K. Management of the newborn infant affected by maternal opiates and other drugs of dependency. J Paediatr Child Health. 2007;43: 9-18.
5. McCarthy JJ. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and meth-adone tapers: can we assure the safety of the fetus? J Matern-Fetal Neo M. 2012;25:109-112.
6. Drozdick J III, Berghella V, Hill M, et al. Meth-adone trough levels in pregnancy. Am J Obstet Gynecol. 2002;187:1184-1188.
7. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and futureinmainstreammedicine. Ann NY Acad Sci. 2000;909:186-216.
8. Rostami-Hodjegan A, Wolff K, Hay AW, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999;48:43-52.
9. Jagsch R, Gombas W, Schindler SD, et al. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients. Addict Biol. 2005;10:365-371.
10. Jones H, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or bupre-norphine exposure. N Eng J Med. 2010;363: 2320-2331.
11. Inturrisi CE, Colburn WA, Kaiko RF, et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987;41:392-401.
12. Ferrari A, Coccia CP, Bertolini A, et al. Meth-adone-metabolism, pharmacokinetics and inter-actions. Pharmacol Res. 2004;50:551-559.
13. Nanovskaya TN, Nekhayeva IA, Hankins GDV, et al. Transfer ofmethadone across the dually per-fused preterm human placental lobule. Am J Ob-stet Gynecol. 2008;198:126e.1-126e.e4. 583-591.
14. Jarvis MA, Wu-Pong S, Kniseley JS, et al. Alter-ations in methadone metabolism during late preg-nancy. JAddict Dis. 1999;18:51-61.
15. Wolff K, Boys A, Rostami-Hodjegan A, et al. Changes to methadone clearance during preg-nancy. Eur J Clin Pharmacol. 2005;61:763-768.
16. Messinger DS, Bauer CR, Das A, et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes ofcocaine-exposed and opi-ate-exposed infants through three years of age. Pediatrics. 2004;113:1677-1685.
17. Patrick SW, Schumacher RE, Bennetworth BD, et al. Neonatal abstinence syndrome and associ-ated health care expenditures: United States, 2000-2009. JAMA. 2012;307:1934-1940.
18. Lester BM, Tronick E, Nestler E, et al. Behavioral epigenetics. Ann N YAcad Sci. 2011;1226:14-33.
19. Brown MS, Hayes MJ, LaBrie S. Breastfeeding is Associated With Decreased Risk and Length of Treatment for Neonatal Abstinence Syndrome in Methadone and Buprenorphine Exposed Infants. Presented at: Pediatric Academic Societies; May 1-4, 2011. Vancouver, BC, Canada. Abstract 2258.
20. Lim S, Prasad MR, Samuels P, et al. High-dose methadone in pregnant women and its effect on duration ofneonatal abstinence syndrome. Am J Obstet Gynecol. 2009;200:70 e71-70 e75.
21. Jansson LM, Dipietro JA, Elko A, et al. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. JMatern Fetal Neo-natalMed. 2007;20:677-685.
22. Jansson LM. Academy ofBreastfeeding Medicine Protocol Committee. ABM clinical protocol #21: guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009;4: 225-228.
23. Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syn-drome in methadone-exposed neonates. Am J Obstet Gynecol. 2008;199:396 e391-396 e397.
24. Wachman E, Hayes M, Paul J, et al. Single Nucleotide Polymorphisms and Variability in Se-verity of Neonatal Abstinence Syndrome. Boston, MA: Pediatric Academic Society.
25. Burns L, Mattick RP, Lim K, et al. Methadone in pregnancy: treatment retention and neonatal out-comes. Addiction. 2007;102:264-270.
26. Pritham UA, Paul JA, Hayes MJ. Opioid depend-ency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs. 2012;41:180-190.
27. Liu AJW, Jones MP, Murray H, et al. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone main-tenance therapy. Aust N Z J Obstet Gynaecol. 2010;50:253-258.
28. Hunt RW, Tzioumi D, Collins E, et al. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev. 2008;84: 29-35.
29. Abdel-Latif ME. Effects of breast milk on the severity and outcome of neonatal abstinence syn-drome among infants ofdrug-dependent mothers. Pediatrics. 2006;117:e1163-e1169.
30. Liu AJ, Nanan R. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. 2008;121:869-870.
31. Bayley N. Bayley Scales ofInfant Development. 2nd ed. San Antonio, TX: The Psychological Corporation; 1993.
32. Kaltenbach K, Finnegan LP. Perinatal and devel-opmental outcome ofinfants exposed to methadone in-utero. Neurotoxicol Teratol. 1987;9:311-313.
33. Bernstein V, Jeremy RJ, Hans SL, et al. A longi-tudinal study of offspring born to methadone-maintained women. II. Dyadic interaction and infant behavior at 4 months. Am J Drug Alcohol Abuse. 1984;10:161-193.
34. Logan BA, Heller NA, Paul JA, et al. Longitudinal Developmental Outcomes in the First Year in Opiate-exposed Infants: Role of Prenatal Alcohol Exposure. Atlanta, GA: Research Society on Alcoholism.
35. Logan BA, Paul JA, Heller NA, et al. Long-term Developmental Outcomes in Infants of Opiate Addicted Women: Effects on Cognitive and Motor Development. Montreal, QB: Society for Research in Child Development.
36. Mattson SN, Riley EP. A longitudinal study of the long-term consequences of drinking during pregnancy: heavy in utero alcohol exposure dis-rupts the normal processes of brain development. J Neuroscience. 2012;32:15243-15251.
37. Logan BA, Krishnan R, Paul J, et al. Neurodeve-lopmental and Motor Sequelae in Methadone-ex-posed Infants: Synergistic Effects of Alcohol. Boston, MA: Pediatric Academic Society.